National oncology center - Royal Hospital, Muscat, Oman.
Icahn school of medicine at Mount Sinai / Queens, New York, USA.
Gulf J Oncolog. 2021 Sep;1(37):56-61.
Breast cancer is the commonest cancer amongst females. The incidence of breast cancer is estimated to be around 260K yearly. Oral hormonal medication is an essential part of the management of breast cancer for hormone receptor-positive patients. Adjuvant hormonal medication is recommended to be taken daily for 5-10 years. Adjuvant hormonal medication reduces mortality by 30% and the recurrence rate in receptor-positive patients.
This study's primary goal is to evaluate the rate of nonadherence to Endocrine Therapy for hormone receptor-positive breast cancer patients at Oman National Oncology Center. This study included patients taking hormonal therapy (either with Tamoxifen or Aromatase inhibitor) and presented for regular followup between June 2019 and February 2020 at the National oncology center, Oman. Data was collected using a written questionnaire. Descriptive analysis was done by using SPSS. A cross-sectional descriptive study for patients taking oral hormonal therapy. 131 patients were included.
One hundred thirty-one patients were included, Tamoxifen was used by 73 (55.73%). 71 (54%) of breast surgery was "WLE" The majority of patients 95 (72.5%) did not identify a specific reason for non-compliance. The most commonly reported adverse effects were musculoskeletal symptoms by 75 patients (57.3%), with other reported side effects included hot flashes (33.6%), anxiety (30.5%), gynecological toxicity (29.8%), decreased concentration (19.1%), neurological symptoms (16%), and depression (9.9%).
We reported that patients with hormone receptor-positive breast cancer have a high adherence rate to the medication than developing countries; selfreported non-compliance to oral hormonal medication is 41.22% below the average of non-compliance to chronic disease therapy of developing countries as WHO report. Medical insurance, unemployment, or drug cost is not a cause for non-compliance to medication.
The self-reported nonadherence to oral hormonal medication is (41,22%). Most of the patients (72.5%) did not report a specific cause for non-adherent to medication. Close follow-up is recommended increasing compliance to medication.
乳腺癌是女性中最常见的癌症。据估计，每年乳腺癌的发病率约为 26 万例。对于激素受体阳性的患者，口服激素药物是乳腺癌治疗的重要组成部分。建议辅助激素药物每天服用 5-10 年。辅助激素治疗可降低 30%的死亡率和受体阳性患者的复发率。
本研究的主要目的是评估阿曼国家肿瘤中心激素受体阳性乳腺癌患者内分泌治疗的不依从率。本研究包括服用激素治疗（他莫昔芬或芳香化酶抑制剂）并在 2019 年 6 月至 2020 年 2 月期间在阿曼国家肿瘤中心定期就诊的患者。使用书面问卷收集数据。使用 SPSS 进行描述性分析。这是一项针对口服激素治疗患者的横断面描述性研究。共纳入 131 例患者，其中 73 例（55.73%）使用他莫昔芬，71 例（54%）行乳房切除术“WLE”。大多数患者 95 例（72.5%）未确定不依从的具体原因。最常报告的不良反应是 75 例患者（57.3%）出现肌肉骨骼症状，其他报告的副作用包括热潮红（33.6%）、焦虑（30.5%）、妇科毒性（29.8%）、注意力不集中（19.1%）、神经症状（16%）和抑郁（9.9%）。
我们报告称，激素受体阳性乳腺癌患者对药物的依从性高于发展中国家；根据世卫组织报告，自我报告的口服激素药物不依从率为 41.22%，低于发展中国家慢性疾病治疗不依从率的平均水平。医疗保险、失业或药物费用不是不依从药物治疗的原因。
自我报告的口服激素药物不依从率为（41.22%）。大多数患者（72.5%）未报告不依从药物治疗的具体原因。建议密切随访，以提高药物依从性。
